Cross-Species Transcriptomic Triangulation and Exploratory LINCS L1000 Reversal in Sepsis-associated ARDS: Integrating Human Blood (GSE66890, GSE32707) and Murine Lung Endothelium (GSE169532)

Background: Sepsis-associated acute respiratory distress syndrome (ARDS) lacks validated host-directed pharmacotherapies capable of reversing pulmonary microvascular endothelial injury. Aims: To integrate human whole-blood ARDS-versus-sepsis transcriptomes with murine pulmonary endothelial responses to prioritise exploratory small-molecule reversal candidates. Study Design: Integrative cross-species transcriptomic meta-analysis and connectivity-reversal pharmacoinformatics study. Place and Duration of Study: CMHC Research Center, Palembang, and ANC Medical Center, Jakarta, Indonesia. Methodology: Human blood cohorts (GSE66890, n = 57 [29 ARDS, 28 sepsis; 18,085 genes]; GSE32707 Day 0, n = 48 [18 ARDS, 30 sepsis; 20,748 genes]; N = 105) were analysed via empirical Bayes limma and DerSimonian–Laird meta-analysis across 17,171 shared genes with reciprocal replication auditing. Estimates were triangulated with murine cecal ligation and puncture lung capillary (capEC, n = 6) and postcapillary venular (PCV, n = 6) endothelial RNA-seq (GSE169532, N = 12) via 1:1 orthology, L1000CDS2, 20 API and 10,000 Monte Carlo random controls, ChEMBL v34, and STRING v12.5. Results: No gene reached FDR < 0.05 in either human cohort alone (80 reached FDR < 0.10 in GSE66890; 0 in GSE32707; Spearman ρ = 0.072; concordant sign 9,111/17,171 [53.06%]). Meta-analysis identified 11 genes at FDR < 0.05; only PIM1 (log2FCmeta = 0.555, SE = 0.123, FDR = 0.019) was concordantly upregulated in murine capEC (log2FC = 1.345, FDR = 0.004) and PCV (log2FC = 1.548, FDR = 0.016). A 38-gene barrier panel showed no enrichment (Mann–Whitney p = 0.513). L1000CDS2 prioritised selumetinib (score = 0.1176 [0.118], A375, 80.0 µM; pemp = 0.0476; pMC = 0.0018), geldanamycin, and AS605240 across three specifications, though none ranked in the GSE32707 top 50. Conclusion: Cross-species integration identifies PIM1 as a convergent node and prioritizes selumetinib, geldanamycin, and AS605240 as preclinical candidates requiring multi-stage experimental and clinical confirmation.

Authors

Publication Details

Journal
Journal of international research in medical and pharmaceutical sciences
Published
2026-11-12
DOI
https://doi.org/10.56557/jirmeps/2026/v21i311360
Primary Topic
Sepsis Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cross-Species Transcriptomic Triangulation and Exploratory LINCS L1000 Reversal in Sepsis-associated ARDS: Integrating Human Blood (GSE66890, GSE32707) and Murine Lung Endothelium (GSE169532)

Kemas Abdul Mutholib Luthfi, Wisnu Wardhana Putra, Cindy Susanti, Oliva Azalia Putri et al.
Journal of international research in medical and pharmaceutical sciences
Sepsis Diagnosis and Treatment
article

Cross-Species Transcriptomic Triangulation and Exploratory LINCS L1000 Reversal in Sepsis-associated ARDS: Integrating Human Blood (GSE66890, GSE32707) and Murine Lung Endothelium (GSE169532)

Kemas Abdul Mutholib Luthfi, Wisnu Wardhana Putra, Cindy Susanti, Oliva Azalia Putri, Fachrudin Sani, Riri Arisanty Syafril Lubis, Habiburrahman Said, Pham Uyen, Muhammad Ashraf, Mustafa Mahmud, Andhika Kurnianta Kusuma
article en

Abstract

Background: Sepsis-associated acute respiratory distress syndrome (ARDS) lacks validated host-directed pharmacotherapies capable of reversing pulmonary microvascular endothelial injury. Aims: To integrate human whole-blood ARDS-versus-sepsis transcriptomes with murine pulmonary endothelial responses to prioritise exploratory small-molecule reversal candidates. Study Design: Integrative cross-species transcriptomic meta-analysis and connectivity-reversal pharmacoinformatics study. Place and Duration of Study: CMHC Research Center, Palembang, and ANC Medical Center, Jakarta, Indonesia. Methodology: Human blood cohorts (GSE66890, n = 57 [29 ARDS, 28 sepsis; 18,085 genes]; GSE32707 Day 0, n = 48 [18 ARDS, 30 sepsis; 20,748 genes]; N = 105) were analysed via empirical Bayes limma and DerSimonian–Laird meta-analysis across 17,171 shared genes with reciprocal replication auditing. Estimates were triangulated with murine cecal ligation and puncture lung capillary (capEC, n = 6) and postcapillary venular (PCV, n = 6) endothelial RNA-seq (GSE169532, N = 12) via 1:1 orthology, L1000CDS2, 20 API and 10,000 Monte Carlo random controls, ChEMBL v34, and STRING v12.5. Results: No gene reached FDR < 0.05 in either human cohort alone (80 reached FDR < 0.10 in GSE66890; 0 in GSE32707; Spearman ρ = 0.072; concordant sign 9,111/17,171 [53.06%]). Meta-analysis identified 11 genes at FDR < 0.05; only PIM1 (log2FCmeta = 0.555, SE = 0.123, FDR = 0.019) was concordantly upregulated in murine capEC (log2FC = 1.345, FDR = 0.004) and PCV (log2FC = 1.548, FDR = 0.016). A 38-gene barrier panel showed no enrichment (Mann–Whitney p = 0.513). L1000CDS2 prioritised selumetinib (score = 0.1176 [0.118], A375, 80.0 µM; pemp = 0.0476; pMC = 0.0018), geldanamycin, and AS605240 across three specifications, though none ranked in the GSE32707 top 50. Conclusion: Cross-species integration identifies PIM1 as a convergent node and prioritizes selumetinib, geldanamycin, and AS605240 as preclinical candidates requiring multi-stage experimental and clinical confirmation.

Journal of international research in medical and pharmaceutical sciencesVol. 21(3)
Good health and well-being
Sepsis Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon